Literature DB >> 29777184

Genotype-phenotype links in frontotemporal lobar degeneration.

Sara Van Mossevelde1,2,3,4, Sebastiaan Engelborghs2,3, Julie van der Zee1,2, Christine Van Broeckhoven5,6.   

Abstract

Frontotemporal lobar degeneration (FTLD) represents a group of neurodegenerative brain diseases with highly heterogeneous clinical, neuropathological and genetic characteristics. This high degree of heterogeneity results from the presence of several different underlying molecular disease processes; consequently, it is unlikely that all patients with FTLD will benefit from a single therapy. Therapeutic strategies for FTLD are currently being explored, and tools are urgently needed that enable the selection of patients who are the most likely to benefit from a particular therapy. Definition of the phenotypic characteristics in patients with different FTLD subtypes that share the same underlying disease processes would assist in the stratification of patients into homogeneous groups. The most common subtype of FTLD is characterized by TAR DNA-binding protein 43 (TDP43) pathology (FTLD-TDP). In this group, pathogenic mutations have been identified in four genes: C9orf72, GRN, TBK1 and VCP. Here, we provide a comprehensive overview of the phenotypic characteristics of patients with FTLD-TDP, highlighting shared features and differences among groups of patients who have a pathogenic mutation in one of these four genes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29777184     DOI: 10.1038/s41582-018-0009-8

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  21 in total

Review 1.  C9orf72-Related Neurodegenerative Diseases: From Clinical Diagnosis to Therapeutic Strategies.

Authors:  Stefania Zampatti; Cristina Peconi; Rosa Campopiano; Stefano Gambardella; Carlo Caltagirone; Emiliano Giardina
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

2.  Recent advances in the genetics of frontotemporal dementia.

Authors:  Daniel W Sirkis; Ethan G Geier; Luke W Bonham; Celeste M Karch; Jennifer S Yokoyama
Journal:  Curr Genet Med Rep       Date:  2019-01-30

3.  Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers.

Authors:  Julia Remnestål; Linn Öijerstedt; Abbe Ullgren; Jennie Olofsson; Sofia Bergström; Kim Kultima; Martin Ingelsson; Lena Kilander; Mathias Uhlén; Anna Månberg; Caroline Graff; Peter Nilsson
Journal:  Transl Neurodegener       Date:  2020-06-23       Impact factor: 8.014

4.  NPM-hMLF1 fusion protein suppresses defects of a Drosophila FTLD model expressing the human FUS gene.

Authors:  Itaru Yamamoto; Yumiko Azuma; Yukie Kushimura; Hideki Yoshida; Ikuko Mizuta; Toshiki Mizuno; Morio Ueyama; Yoshitaka Nagai; Takahiko Tokuda; Masamitsu Yamaguchi
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

5.  Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort.

Authors:  Bin Jiao; Qiying Sun; Zhenhua Yuan; Junling Wang; Lin Zhou; Xinxiang Yan; Beisha Tang; Lu Shen
Journal:  Transl Neurodegener       Date:  2018-12-04       Impact factor: 8.014

Review 6.  Pathogenesis of Frontotemporal Lobar Degeneration: Insights From Loss of Function Theory and Early Involvement of the Caudate Nucleus.

Authors:  Gen Sobue; Shinsuke Ishigaki; Hirohisa Watanabe
Journal:  Front Neurosci       Date:  2018-07-12       Impact factor: 4.677

7.  Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons.

Authors:  Lien-Szu Wu; Wei-Cheng Cheng; Chia-Ying Chen; Ming-Che Wu; Yi-Chi Wang; Yu-Hsiang Tseng; Trees-Juen Chuang; C-K James Shen
Journal:  Acta Neuropathol Commun       Date:  2019-03-29       Impact factor: 7.801

8.  The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications.

Authors:  Helena Gossye; Christine Van Broeckhoven; Sebastiaan Engelborghs
Journal:  Front Neurosci       Date:  2019-08-06       Impact factor: 4.677

Review 9.  Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease.

Authors:  Sophia R L Vieira; Huw R Morris
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

10.  Protein-protein interactions reveal key canonical pathways, upstream regulators, interactome domains, and novel targets in ALS.

Authors:  Ina Dervishi; Oge Gozutok; Kevin Murnan; Mukesh Gautam; Daniel Heller; Eileen Bigio; P Hande Ozdinler
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.